PITTSBURGH, Aug. 21 /PRNewswire/ -- Cellumen, Inc., the Cellular Systems Biology Company, announced today that Dr. Rosemary Mazanet has joined the Board of Directors of Cellumen, Inc. Dr. Mazanet is presently serving as the CEO of Breakthrough Therapeutics, LLC and as acting CEO of Access Pharmaceuticals . Previously, Dr. Mazanet has served as the CSO and General Partner of Oracle Partners, L.P. and prior to that was the Director of Clinical Research at Amgen, Inc. In addition, Dr. Mazanet is a member of the Board of Trustees of the University of Pennsylvania School of Medicine and serves on the Board of several public companies including GTx, Inc. and Aksys Inc.
“We are pleased to have attracted a board member with the breadth of experience and record of accomplishment that has characterized Dr. Mazanet’s career,” stated D. Lansing Taylor, CEO of Cellumen. “Rosemary adds an important dimension to our already distinguished Board.”
Dr. Mazanet commented that “With the right focus and systems biology tools, the ability to understand disease processes will lead us to better treatments. The approach at Cellumen is on track to realize this goal.”
About Cellumen, Inc.
Cellumen is the Cellular Systems Biology Company that is focusing on the cell as an integrated and interacting network of genes, proteins and metabolites that are responsible for normal and abnormal functions. Cellumen is directly pursuing the two main issues of efficacy and toxicity that limit the efficiency of drug discovery. The Cellumen products and services address “cellular models of disease,” “cytotoxicity profiling” and “patient sample profiling.” Cellumen leverages the experience and expertise in High Content Screening, as well as advanced reagents and informatics to create high value solutions. Further information can be found at www.cellumen.com
Cellumen, Inc.
CONTACT: Tim O’Brien of O’Brien Communications, +1-412-854-8845, forCellumen, Inc.
